Drug intelligence / Profile preview

Alterion

Development stage: Unknown
Lead developer: Aventis Animal Nutrition
Modality: Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics

Overview

Alterion is a probiotic developed jointly by Adisseo and Novozymes for use in poultry. It is designed as a sustainable alternative to antibiotic growth promoters in animal farming. The product is based on a unique strain of *Bacillus subtilis* and was launched in 2016. Novozymes is responsible for its in-vitro screening, development, and production, while Adisseo manages in-vivo testing, marketing, and sales.

Brand names: Alterion

Beyond the preview

Go deeper on Alterion.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alterion.

Explore the full profile